If you've been relying on compounded semaglutide for weight loss, the clock has run out. The FDA has been systematically shutting down compounding pharmacies producing semaglutide copies throughout 2025 and 2026, and the supply of legitimate compounded GLP-1 medications has effectively dried up. But here's the important part: affordable branded alternatives now exist that didn't exist when most patients first turned to compounding.
What Happened: The FDA Enforcement Timeline
The compounded semaglutide market existed because of a specific legal window — and that window has closed:
2022–2023: The Shortage Era
When Ozempic and Wegovy faced severe supply shortages, the FDA placed semaglutide on its official drug shortage list. Under federal law, this allowed compounding pharmacies to legally produce semaglutide copies to meet patient demand. Compounded semaglutide exploded in popularity, with hundreds of pharmacies and telehealth platforms offering it at $150–$300/month — a fraction of the branded retail price.
Late 2024: Shortage Resolved
The FDA removed semaglutide from the shortage list in late 2024, signaling that Novo Nordisk had resolved its supply issues. This removed the primary legal basis for most compounding activities. However, enforcement was initially slow, and many pharmacies continued operating.
2025: Enforcement Ramps Up
- Warning letters sent to dozens of compounding pharmacies
- Novo Nordisk filed lawsuits against major compounders, with several resulting in injunctions and settlements
- State pharmacy boards began investigating and revoking licenses of non-compliant pharmacies
- Telehealth platforms that previously offered compounded semaglutide pivoted to branded medications
2026: The Shutdown
By early 2026, the vast majority of legitimate compounding pharmacies have stopped producing semaglutide. Some holdouts continue, but they're operating in an increasingly hostile regulatory environment. Patients using these remaining sources face three risks:
- Quality uncertainty: Without FDA oversight, potency, purity, and sterility cannot be guaranteed
- Supply disruption: Your pharmacy could be shut down at any time, leaving you without medication
- Legal exposure: While patients generally aren't targeted, purchasing from non-compliant pharmacies carries increasing legal ambiguity
Your Best Branded Alternatives, Ranked by Cost
1. Foundayo (Orforglipron) — $149/month starting
Best overall value for former compounded semaglutide users.
Foundayo is the standout option for patients transitioning from compounded semaglutide:
- Price: $149/month for the starting dose through LillyDirect — comparable to what most patients paid for compounded versions
- Format: Daily oral pill — no injections, no needles, no cold storage, no sharps disposal
- Convenience: Take any time of day, with or without food. No fasting, no water restrictions
- Weight loss: Approximately 12.4% body weight in completers — slightly less than injectable semaglutide, but in the same range
- Savings card: Commercially insured patients can get it for $25/month
The transition from injectable compounded semaglutide to oral Foundayo is a change in both molecule and delivery method. You'll start at 0.8 mg and titrate up regardless of your previous compounded dose. See our compounded semaglutide to Foundayo switching guide for detailed transition advice.
2. Oral Wegovy (Semaglutide Tablets) — $149/month starting
Best for patients who want to stay on semaglutide.
If you've been on compounded semaglutide and want to continue with the same molecule, oral Wegovy is the most natural transition:
- Same active ingredient: Semaglutide — your body already knows this molecule
- Potentially faster adjustment: Since you've been on semaglutide, the titration period may be more comfortable
- Price: Starting at approximately $149/month for lower doses
- Trade-off: Requires empty-stomach dosing with a 30-minute fasting window each morning
- Weight loss: Approximately 16.6% in completers — potentially better than Foundayo
3. Zepbound (Tirzepatide) — $299–$549/month via LillyDirect
Best for patients who want to upgrade to the most effective GLP-1.
- Strongest weight loss: Approximately 22.5% in completers — significantly more than semaglutide
- Dual mechanism: GIP + GLP-1 agonism may provide additional metabolic benefits
- Weekly injection: Same administration route as compounded semaglutide (if you were injecting)
- Price: $299/month starting dose, up to $549/month at higher doses
4. Ozempic (Semaglutide Injection) — $936/month retail
The direct branded equivalent of compounded semaglutide, but at a premium price.
- Same molecule, same route: The most direct swap from compounded semaglutide
- Price: Approximately $936/month retail — significantly more expensive than compounded versions
- Savings card: Commercially insured patients may qualify for copay assistance
- Note: Ozempic is FDA-approved for diabetes, not weight loss. Off-label prescribing is common but may affect insurance coverage
How to Transition Successfully
Don't Wait Until Your Supply Runs Out
The worst time to transition is when you've taken your last compounded dose and have nothing to replace it with. Start the process now:
- Talk to your prescriber about which branded alternative is right for you
- Check insurance coverage — formularies have improved significantly for GLP-1 medications in 2026
- Set up LillyDirect or Ro if you're going the self-pay route
- Plan for titration — you'll likely start at the lowest dose of any new medication
Expect a Transition Period
Even if you've been on high-dose compounded semaglutide, you'll typically start at the beginning of the titration schedule for any new branded medication. This is because:
- Compounded medication potency is variable — your actual dose may have been different from what was labeled
- Different molecules (orforglipron vs. semaglutide vs. tirzepatide) have different dose-response relationships
- Safety protocols require gradual titration to minimize side effects
During this titration period, some weight regain is possible. Minimize it by maintaining the healthy eating habits you developed while on medication, continuing or increasing physical activity, and starting the new medication as quickly as possible.
Apply for Every Savings Program Available
- Manufacturer savings cards: Foundayo, Zepbound, and Ozempic all offer $25/month copay cards for commercially insured patients
- Patient assistance programs: Both Lilly and Novo Nordisk offer free medication for qualifying low-income patients
- GoodRx: Compare prices across pharmacies if you're not using LillyDirect
- Insurance appeals: If your insurance denies coverage, file an appeal — denial overturn rates have been improving
The Bigger Picture
The end of compounded semaglutide feels like a loss for patients who depended on it, and that frustration is valid. Compounded medications filled a real gap when branded GLP-1s were either unavailable or unaffordable for most people.
But the market has fundamentally changed. Branded GLP-1 medications are now available at prices that compete with compounded versions — Foundayo at $149/month, oral Wegovy at $149/month for starting doses. The value proposition of compounding — cheap access to a medication that's otherwise unaffordable — no longer holds in the way it did in 2022–2023. See our Foundayo vs compounded semaglutide comparison for a detailed side-by-side analysis.
For a complete breakdown of every GLP-1 option available without insurance, see our guide to GLP-1s without insurance in 2026.
Bottom Line
The compounded semaglutide era is over, but the affordable GLP-1 era is just beginning. Foundayo at $149/month and oral Wegovy at $149/month offer legitimate, FDA-approved alternatives at prices that rival what most patients were paying for compounded versions. The transition requires planning — talk to your prescriber, evaluate your options, apply for savings programs — but the outcome can be a safer, more reliable medication regimen. Stop waiting for compounded semaglutide to come back. It's not coming back. But better options are already here.
Sources
- FDA. "FDA Actions on Compounded Semaglutide Products." Updated February 2026.
- Novo Nordisk. "Legal Proceedings Regarding Compounded GLP-1 Products." 2025–2026.
- Eli Lilly and Company. LillyDirect Pricing for Foundayo and Zepbound. April 2026.
- Novo Nordisk. Oral Wegovy Pricing and Access. 2026.
- FDA. "Compounding and the FDA: Questions and Answers." Updated March 2026.